Abstract
Purpose: To investigate the effect of combined treatment with Yiqi Jianpi Yangxue Decoction and chemotherapy (carboplatin + paclitaxel) on quality of life (QOL) and adverse reactions of patients with recurrent ovarian cancer (ROC).Methods: One hundred and fourteen (114) ROC patients in The Second Children & Women’s Healthcare of Jinan City were split into chemotherapy group (n = 60) and combination group (n = 54), based on whether or not they were treated with Yiqi Jianpi Yangxue Decoction. Differences in clinical efficacy, adverse reactions, levels of tumor marker, levels of immune indexes, and scores on Karnofsky Performance Status (KPS) between the two groups were evaluated.Results: Treatment effectiveness was higher in the combination group than in the chemotherapy group (p < 0.05). Compared with the chemotherapy group, post-treatment levels of HE4 and CA125 in the combination group were lower, while the levels of CD3+, CD4+ and CD8+, and population of NK cells were higher (p < 0.05). After treatment, the KPS score in the combination group was higher than the corresponding score in the chemotherapy group (p < 0.05).Conclusion: Combination of Yiqi Jianpi Yangxue Decoction and chemotherapy (carboplatin + paclitaxel) produces significant enhancement of clinical efficacy in the treatment of ROC. The combination treatment is highly safe, and improves the health status and QOL of patients. Therefore, the combination treatment appears to be suitable for the management of ovarian cancer.
Highlights
Ovarian cancer (OC), a malignant tumor in the female reproductive organs, may occur at any age, but it is seen mostly in women over 50 years old [1,2,3]
Patients in the following categories were included in the study: those who were confirmed to have ovarian cancer after postoperative pathological examination, patients who were stable after undergoing six cycles of chemotherapy, those with increased serum levels of carbohydrate antigen 125 (CA125), patients with lesions that were measurable with computed tomography (CT), ultrasound and magnetic resonance imaging (MRI) after chemotherapy, and patients with Eastern Cooperative Oncology Group (ECOG) score less than 2 points
This study has demonstrated that the combination of Yiqi Jianpi Yangxue Decoction and chemotherapy significantly enhanced clinical efficacy in the treatment of recurrent ovarian cancer (ROC)
Summary
Ovarian cancer (OC), a malignant tumor in the female reproductive organs, may occur at any age, but it is seen mostly in women over 50 years old [1,2,3]. Yiqi Jianpi Yangxue Decoction is a newly developed type of traditional Chinese medicine (TCM) which exerts an adjuvant effect on middle and advanced forms of ovarian cancer [9]. Nowadays, limited reports have been observed on the treatment of recurrent ovarian cancer (ROC) using combination of Yiqi Jianpi Yangxue Decoction and chemotherapy. This paper was to explore the clinical effect of combined use of Yiqi Jianpi Yangxue Decoction and chemotherapy in the treatment of ROC. The effects of this therapy on quality of life (QOL) and adverse reactions were determined, with a view to providing a new research direction for improved clinical treatment of ROC
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
